Investigational

We are not able to offer medical, pharmaceutical or nutritional advice. Please consult a healthcare professional.

Brand Name Generic name IBS type Type Comments
Bekinda® ondansetron IBS-D A patent-protected, extended-release (24 hours) oral pill formulation of ondansetron. Ondansetron is a 5-HT3 antagonist.
Blautix All IBS types Single-strain bacteria that consumes gases which are known to cause bloating, abdominal pain and changes in bowel frequency.
Ibodutant® tachykinin NK2 IBS-D Tachykinin NK2 receptor antagonist. Proposed as a potential novel drug for the therapy of gastrointestinal diseases characterized by motility alterations, visceral pain, and/or inflammation, such as IBS.
IBset® / Nasea® / Nozia® / Irribow® ramosetron IBS-D Improves abnormal bowel movement associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It also improves visceral hypersensitivity by suppressing the transmission of intestinal nociception.
SYN-010® lovastatin lactone IBS-C A proprietary, modified-release formulation of lovastatin lactone that is designed to reduce methane production in the intestine, curbing IBS-C.
Tenapanor® NHE3 IBS-C Non-systemic small molecule inhibitor of NHE3, a sodium transporter present on the epithelia surface of the GI tract. Reduces the absorption of dietary sodium and phosphorus thereby relieving IBS-C.
Trulance® / Plecanatide® guanylate cyclase-C agonist IBS-C Prescription Stimulate digestive fluid movement and support regular bowel function. Trulance (plecanatide) is approved for the treatment of Chronic Idiopathic Constipation (CIC) in adult patients in the United States. In June 2017, the FDA agreed to review supplemental data for approval for the additional indication of IBS-C.